#ES­MO20: Re­gen­eron, Sanofi eye an­oth­er first for their PD-1 con­tender Lib­tayo with promis­ing da­ta for on­col­o­gy niche

Re­gen­eron and Sanofi took an­oth­er step for­ward in the long march to­wards a great­ly ex­pand­ed mar­ket for their late-bloomer PD-1 check­point Lib­tayo.

The two oc­ca­sion­al al­lies post­ed an ob­jec­tive re­sponse rate of 31% for Lib­tayo among 84 pa­tients suf­fer­ing from ad­vanced cas­es of basal cell car­ci­no­ma at vir­tu­al ES­MO. That spot­lights progress for 26 pa­tients, 5 of whom had a com­plete re­sponse. The da­ta al­so re­flect a boost in the num­ber of re­spons­es seen from the last cut of the num­bers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER